Clinical TrialsA key clinical study in Parkinson's disease is expected to yield top-line results, potentially paving the way for new therapeutic uses of nicotinamide riboside.
Financial PerformanceRevenue outperforms expectations, with Niagen Bioscience reporting $30.5M in top-line revenue, exceeding forecasted figures.
Market ExpansionNiagen IV broadens U.S. clinic footprint, poised for further rapid market uptake.